Role of receptor-associated 39/45 kD protein in active Heymann Nephritis. Active Heymann nephritis (HN) of rat, an autoimmune gbmerular disease, is an experimental model of human membranous gbmerulonephropathy (MGN), a common human glomerular disease. The putative autoantigen of HN is believed to be a large glycoprotein (gp330) present in kidneys of rat and human. Gp330 has sequence homology to low density lipoprotein receptor-related protein (LRP)/a2-macroglobulin receptor and co-purifies with another 45 kD protein called receptorassociated protein (RAP) which binds to both gp330 and LRP/a2macroglobulin receptor. Since RAP co-purifies with gp330 and is thus present in the immunizing material used to induce active HN, the present study was undertaken to determine if gp330 or RAP individually could produce active HN and whether RAP had a role in the pathogenesis of active HN. Rats immunized with the traditional crude antigen (Fx1A) containing both gp330 and RAP developed typical HN. Although these rats developed low titers of autoantibody to RAP in their sera, they had no deposition of antibody to RAP in their kidneys. Rats immunized with gp330 also developed typical HN but had no autoantibody to RAP in their sera or kidneys. Rats immunized with RAP developed high titers of autoantibody to RAP in their sera but had no antibody in their kidneys and did not develop HN. Three rats were injected intravenously with polyclonal antibody to RAP and assessed seven days later for the development of passive HN. All three developed mild passive HN characterized by granular staining of polyclonal antibody along the capillary loops. Conclusions: (1) This is the first report to show that gp330 alone without the accompanying RAP can induce active HN; (2) RAP by itself does not induce active HN; (3) Autoantibodies to RAP do not appear to be involved in the pathogenesis of active HN induced with the traditional crude antigen, Fx1A; and (4) We confirm that polyclonal antibody to RAP can induce passive HN. Active Heymann nephritis (HN) of rat is an autoimmune glomerular disease which has striking immunohistobogical, ultrastructural, and clinical similarities to the human idiopathic membranous glomerulonephropathy (MGN) and is widely used as an experimental model for MON [1, 21. It is commonly produced by immunizing rats with an emulsion of complete Freund's adjuvant (CFA) and a crude renal cortical fraction called Fx1A [3]. The putative autoantigen of HN is a mannose or glucose containing large glycoprotein [4, 5] present on proximal renal tubular epithehal cell [6, 7] and visceral glomerular epithelial cell [8]. The disease results from the binding of autoantibodies to the autoantigen expressed on glomerular epithelial cell, leading to the
the more commonly used terminology. Although recent work from several laboratories, [14] [15] [16] [17] [18] supports our estimate of its molecular weight, to prevent confusion we have elected to retain the term gp330 in this communication. gp330 has also been shown to be present in human kidney [19] . Partial cDNAs of rat gp330 have been cloned [20] and show homology to low density lipoprotein [LDL] receptor [21] and LDL receptor related protein (LRP)/a2-macroglobuhin receptor [22] [23] [24] . Recently, plasminogen [251, plasminogen activator-inhibitor complex [16, 18] , hipoprotein lipase [16, 17] , and lactoferrin [16] have been identified as ligands for gp330. We first showed that another kidney protein of 45 kD with eDNA distinct from the eDNA of gp330 could also bind to gp330 when tested by Western analysis [26, 27] . Subsequently, this protein, 39 kD in humans [28] and 45 kD in rat [27] , has been identified to be associated with gp330 and LRP and thus designated receptor associated protein (RAP) [15, 28] . RAP co-purifies with gp330 during laboratory isolation of gp330 through lectin affinity chromatography [15] and is thus present in gp330 preparations used to immunize rats to induce active HN. The purpose of this study was to determine if RAP or gp330 alone could produce active RN and to study the role of RAP in the pathogenesis of active HN induced by active immunization with the traditional crude antigen, FX1A. Time post-injection, weeks Autoantibody to RAP in serum measured by ELISA. Serum samples from week zero (pre-immunization) to week 16 (sacrifice time) from 10 rats immunized with rat Fx1A (•) and 10 rats immunized with GST-RAP fusion protein (0) were tested by ELISA on microtiter plates coated with electroeluted purified RAP. Autoantibody measured as absorbance at 490 nm is shown along the y axis and time (weeks) following the first immunization along the x axis. Serum samples from rats immunized with GST-RAP fusion protein were diluted 1:8000 and those from immunized with rat Fx1A diluted 1:50. Thus, the curve depicting autoantibody level in RAP immunized rats was generated from sera that were 160-fold dilute than the sera used to generate the curve for FX1A immunized rats. Antigens Rat crude kidney antigen (Fx1A) was prepared from rat kidneys as described before by Edgington et al [31. Rat gp330 was prepared from sodium desoxycholate solubilized rat Fx1A by gel filtration, lectin affinity chromotography and electroelution of the gp330 band from a preparative SDS-PAGE gel as described previously [29] . The electroeluted gp330 band was again tested for purity and contained no RAP as assessed by SDS-PAGE and Western blot analysis using rabbit polyclonal antibody to rat RAP. Rat recombinant RAP was prepared as follows.
Purification of glutathione S-transferase, GST-RAP fusion protein. The salmonella japonicum glutathione S-transferase (GST)-RAP expression plasmid containing full length cDNA of rat RAP was a gift of Dr. Joachim Herz [30] . GST-RAP fusion protein was overexpressed in DH5a bacteria and purified by affinity chromatograpgy on a glutathione-agarose column as described by Herz et al [30] . The purity of GST-39 kD fusion protein was assessed by SDS-PAGE. This GST-RAP fusion protein was used as an immunogen to immunize rats to induce AHN.
Purification of RAP. Since rats were immunized in the GST-RAP fusion protein, they could make antibodies to both GST and RAP. In order to differentiate these antibodies by ELISA and / Fig. 4 . Autoantibody to RAP in serum detected by indirect immunofluorescence. Serum from a rat immunized with GST-RAP fusion protein was studied by indirect immunofluorescence on a snap-frozen unfixed normal rat kidney section (4 m) using FITC labeled rabbit anti-rat IgG. Fluorescence in the brush border microvillar region of proximal renal tubules is seen (magnification 400X).
Western blot analysis, a preparation of RAP without the accompanying GST was needed. To prepare RAP without GST, the GST-RAP fusion protein was subjected to two additional purification steps. First, the RAP was cleaved off from the GST-RAP fusion protein by thrombin treatment. Fractions of GST-RAP fusion protein were pooled and dialyzed against 20 mrvi Hepes, 50 mM NaC1, 2.5 mvt CaC12 pH 7.4, and incubated with 3 U of thrombin/5 mg of fusion protein at 37°C. After four hours, another three U of thrombin/5 mg protein were added and incubation continued overnight. Reaction was stopped by adding PPACK at a ratio of io mole of PPACK to 10-8 mole of thrombin. The digested protein solution was reapplied to freshly equilibrated glutathione-agarose column and the unabsorbed material containing the cleaved purified recombinant RAP saved and analyzed for purity by SDS-PAGE. Second, the above RAP was further purified by preparative PAGE on a 3 mm thick 10% SDS-PAGE gel under non-reducing conditions by using the 
Induction of active HN
Active HN was induced in female Lewis rats in a standard manner by immunizing with the test antigen emulsified in CFA, as described previously [12] . Group 1 (N = 10) was immunized with rat Fx1A, group 2 (N = 10) with recombinant rat GST-RAP fusion protein, and group 3 (N = 3) with purified electroeluted rat gp330 band. The first immunization was given intracutaneously, divided among one hind foot pad and multiple sites on back. Booster immunizations were given subcutaneously at four and eight weeks, respectively, after the first immunization. For the first immunization each rat in group 1 received 10 mg of Fx1A, in group 2, 500 g of GST-RAP fusion protein, and in group 3, 100 ig of rat gp330, respectively. The dose for the booster immunizations was one-half of the dose of the first immunization for each antigen. Sera were collected prior to immunization and every 4 weeks subsequently. Twenty-four urines were collected prior to immunization and every two weeks, starting at six weeks of the first immunization. Total protein in urines was determined by sulfosalicylic acid method as described previously [12] . Rats were sacrificed at 16 weeks, and their kidneys analyzed for the development of active HN by performing direct immunofluorescence on snap-frozen unfixed kidney sections for the presence of typical staining for rat IgG and C3 complement in glomeruli. The technique for processing of tissue and immunofluorescence has been previously described [32] . One kidney from each rat was used to isolate glomeruli and elute IgG from glomeruli using an acid buffer. The techniques for isolation of glomeruli and elution of IgG from glomeruli have been described previously [29] .
Enzyme-linked immunosorbent assay (ELISA) Antibodies to RAP were determined by ELISA using the standard ELISA procedure previously described in detail [33] .
Briefly, microtiter plate wells were coated with purified thrombin cleaved RAP or electroeluted RAP (5 j.g/ml) and reacted sequentially with test sera, peroxidase labeled goat anti-rat IgG and substrate solution (2.5 mM 0-phenylenediamine, 0.006% H202, 0.1 M phosphate/citrate buffer, pH 5.0) and the absorbance read at 490 nm before and after the addition of 50 d of 4N H2S04.
Appropriate controls of reaction of preimmune normal rat serum and peroxidase-labeled goat anti-rat IgG alone on RAP coated wells, and reaction of immune rat serum, normal rat serum and peroxidase-labeled goat anti-rat IgG on non-RAP coated wells (BSA) were included. All samples were analyzed in duplicates.
The mean absorbance of duplicates was calculated and the background absorbance obtained with control samples subtracted from the above mean. Titers of antibody in sera were determined from serial dilutions of sera. The dilution immediately preceding the highest dilution at which no autoantibody was detectable (that is, absorbance value was similar to background) was considered as the titer.
SDS-PAGE and Western analysis
Proteins were electrophoresed in 10% or 4 to 15% gradient polyacrylamide gels under non-reducing conditions by using the discontinuous buffer system of Laemmli [31] and transferred to nitrocellulose as described before [33] . Nitrocellulose membrane was blocked and reacted sequentially with test sera, peroxidaselabeled goat anti-rat IgG, and substrate solution (0.05% 4-chloro-1-napthol, 15% methanol, 0.015% H2O2 in PBS) as described previously [33] . Appropriate controls of reaction with normal rat serum and peroxidase-labeled second antibody alone were included.
Induction of passive HN
A polyclonal antibody to rat RAP was prepared in rabbit by immunizing with purified RAP. The antibody was characterized for specificity by indirect immunofluorescence, ELISA and Western blot analysis and found to be specific. Three normal rats were injected intravenously with 1 ml of the antiserum each. The rats were sacrificed a week later and their kidneys examined by direct immunofluorescence for localization of rabbit IgG and rat IgG, C3 and C5b-9. Twenty-four urines were collected prior to injection with antibody and prior to sacrifice and tested for total protein.
Results
Purification of rat RAP Successive purification of recombinant rat RAP from cell lysate containing GST-RAP fusion protein through glutathione-agarose affinity chromatography, thrombin cleavage of GST-RAP fusion protein followed by passage through glutathione-agarose column, and isolation of the RAP band by electroelution from preparative PAGE gel resulted in a highly purified preparation of RAP.
Minor impurities were present in the preparation obtained from glutathione-agarose affinity column following application of the cell lysate. However, these impurities were eliminated during further purification following thrombin cleavage and preparative PAGE, and the final product was pure and homogeneous, as assessed by SDS-PAGE (Fig. 1) . The identity of the isolated RAP was further confirmed by Western analysis using a polyclonal antibody to native rat RAP produced as described earlier [27] . A single band of reactivity was seen with this antibody by Western analysis. Purified RAP was also tested for binding to gp330 by ELISA and was found to bind to gp330.
Role of RAP in active HN
Immunization of rats with GST-RAP fusion protein RAP. All ten rats immunized with recombinant RAP fusion protein developed autoantibodies to RAP. The autoantibodies were detectable in serum at the time of the first bleed (4 weeks) and throughout the course until the rats were sacrificed at 16 weeks. The autoantibodies were detectable by ELISA, Western blot analysis, and indirect immunofluorescence on frozen, unfixed normal rat kidney sections. At time of sacrifice, the titer of autoantibodies in individual rats ranged from 1:10 to 1:100 by indirect immunofluorescence and 1:64,000 to 1:256,000 by ELISA. No differences in titers of autoantibody in RAP were seen by ELISA on plates coated with RAP prepared by thrombin cleavage alone or electroelution following thrombin cleavage. Antibody level as measured by absorbance at 490 nm by ELISA gradually increased from week 4 to week 12 (Fig. 2) . The results of autoantibody detection from a rat at time of sacrifice by Western blot analysis are shown in lane 5 in Figure 3 and by indirect immunofluorescence in Figure 4 . By indirect immunofluorescence the autoantibody reacted with RAP present in the brush border region of the proximal renal tubules on unfixed sections and with RAP in the cytoplasm on periodote/lysine/paraformadehyde (PLP) fixed sections. No specific reaction was seen in glomeruli. Analyses of kidneys at time of sacrifice by direct immunofluorescence showed no granular staining typical for HN in glomeruli for rat IgG, or C3 and C5b-9 membrane attack components of complement in any rat. Minimal staining for rat IgG in glomeruli was present ( Fig.  5a ), but it was no different in quantity or pattern of staining than the control staining for endogenous rat IgG usually present in normal rat kidney sections (Fig. Sb) . No autoantibody to RAP could be detected by any of the three methods in the glomerular eluates in any rat. Protein excretion in 24 hour urine samples in all these rats remained low (0.64 0.18 mg, mean SEM) and was in the normal range throughout the course (Fig. 6 ). The normal range of protein excretion in eight age and sex matched control rats immunized with CFA only was 1.0 0.35 mg (mean sEM).
Immunization of rats with rat FxJA. All ten rats immunized with rat Fx1A developed HN with typical immunohistology of MGN consisting of granular staining for rat IgG (Fig. Sc) , C3 and C5b-9 along capillary loops, and abnormal 24 hour proteinuria (Fig. 6 ). The mean SEM protein excretion in 24 hour urine collections at 14 weeks after the first immunization was 58. 18 12.71 . All these rats also developed autoantibodies to RAP as detected by ELISA; however, the titers were only 1:50 to 1:100 (Fig. 2) . Since both anti-gp330 and anti-RAP autoantibodies react with the same anatomic site on proximal renal tubule, they could not be differentiated by indirect immunofluorescence on frozen unfixed rat kidney sections. However, they may be differentiated on PLP fixed sections [27, 28] . On PLP fixed sections serum from these rats reacted with only the brush border of proximal renal tubules and no intracytoplasmic reaction was seen. This suggests that the titer of autoantibody to RAP was very low. This is consistent with the low titers detected by ELISA, which is a more sensitive assay than indirect immunofluorescence. Faint reaction suggestive of low level of autoantibody to rat RAP could be detected by Western blot analysis; however, we could not photograph this faint reaction. No autoantibody to RAP was detectable by any of the three methods in the IgG eluted from glomeruli of rats immunized with Fx1A.
Immunization of rats with rat gp330. All three rats immunized with rat gp330 also developed typical immunohistology of MGN ( Fig. 5c ) like the rats immunized with rat Fx1A, but had less quantitative proteinuria (2.4 to 46.9 mg/24 hr). None of the rats injected with rat gp330 developed autoantibodies to RAP, as assessed by ELISA, Western blot analysis (Fig. 3) or indirect immunofluorescence on PLP fixed sections (cytoplasmic fluorescence). No autoantibody to RAP was detectable in IgG eluted from glomeruli of these rats.
Immunofluorescence studies on liver of GST-RAP fusion protein immunized rats Since RAP is present in hepatic cells, we analyzed frozen liver sections for in-vivo localization of rat IgG by direct immunofluorescence. No specific immunofluorescence for rat IgG was present in livers of any of the animals, suggesting that in vivo no binding of anti-RAP autoantibodies occurred in hepatocytes.
Passive HN induced by anti-RAP serum
In all three rats, small granular deposits staining for rabbit IgG and rat C5b-9 were seen along the periphery of glomerular capillary loops (Fig. 7) . No staining was present for rat IgG. The protein excretion in urine was in the normal range.
Discussion
This is the first report to show that immunization with gp330 alone can induce active HN in rat. In all previous reports [8, 10-12, 29, 34, 35] the gp330 or like preparations used to induce active HN were most likely contaminated with RAP. This assertion is based on the recent knowledge that RAP is noncovalently bound to gp330 with high affinity (Kd = 8 nM) and invariably co-purifies with gp330 [15] . Since none of the previously used preparations of gp330 was tested for RAP, and in no case was an isolated 330 kD band used for immunization, it is likely that they all contained RAP. We subjected the traditional gp330 preparation to preparative PAGE and immunized animals with only the gp330 band which did not contain RAP. Thus, gp330 alone without the accompanying RAP can induce active HN.
The results of this study also provide evidence that RAP by itself is not involved in the induction of active HN and that autoantibodies to it do not accumulate in glomeruli of rats with active HN. The evidence for this assertion is three-fold. First, effective immunization with GST-RAP fusion protein does not lead to the glomerular lesion of MGN. Second, in rats with active HN induced by Fx1A that contains native RAP, no antibody to RAP can be eluted from the glomerular lesion of MGN. Third, immunization with gp330 alone can produce active HN and no autoantibodies to RAP develop in these animals.
Immunization with RAP was performed with a fusion protein consisting of GST and recombinant RAP obtained from a full length cDNA of RAP. Therefore, it is likely that it contained the immunogenic epitopes present on native RAP. Clearly, the immunizations were effective, since all ten immunized rats produced large amounts of autoantibodies to RAP. However, none of the rats had glomerular accumulation of anti-RAP autoantibodies in their kidneys or developed abnormal proteinuria. Why the anti-RAP autoantibodies in vivo do not localize in the glomerulus is not clear. One possibility is that in vivo RAP is not expressed on cell surface in the glomerular capillary wall in sufficient amounts to form antigen-antibody complexes. This notion is consistent with the recent results of Abbate et al [36] . These investigators performed studies to explain the observations made earlier by Orlando et al [37] . The latter investigators had observed that anti-RAP antibodies, when studied immunohistologically, reacted within the cytoplasm with the rough endocytoplasmic reticulum (RER) in tissue sections fixed in periodate/lysine/paraformaldehyde (PLP), and with the brush border of microvilli in snap frozen unfixed or acetone fixed tissue sections. Abbate et al confirmed the findings of Orlando et al, but showed that the brush border reaction of anti-RAP antibodies detected in unfixed snap-frozen sections is due to an artifactual redistribution of endogenous RAP that occurs during tissue processing. Their results showed that during incubation of snap-frozen tissue section, endogenous RAP was released in soluble form from its intracellular location in RER and bound by gp330 present on the brush border of proximal tubules. They also showed that endogenously RAP is present in the cytoplasm but very little, if any, on cell surface of tubular or glomerular cells. Prior to these studies, Kounnas et al had also made a similar observation [15] . It is noteworthy that while gp330 could be readily demonstrated on the surface of the glomerular podocytes, no RAP was detected on glomerular podocytes immunohistochemically by electron microscopy, by neither Orlando et al [37] nor Abbate et al [36] . These studies suggest that in vivo most of the RAP is present in the cytoplasm of the glomerular epithelial cell and probably not available for interaction with the circulating anti-RAP autoantibody bathing the surface of the glomerular epithelial cell in the glomerular capillary wall. Another possibility is that a small amount of RAP that is present on surface does not contain the epiotopes to which the autoantibodies are formed, since the autoantibodies are most likely elicited against only a limited number of epitopes. It is also possible, as suggested by Kounnas et al [15] , that when RAP is bound to cell surface receptors, such as the a2MR/LRP or gp330, the pathogenic epitopes are hidden or masked. This may explain why no glomerular accumulation of RAP autoantibody and a lesion like Heymann nephritis was seen in animals immunized with OST-RAP fusion protein. A similar explanation may also be responsible for the lack of localization of anti-RAP autoantibodics in vivo in the liver. Our results differ from those reported by Pietromonaco et al [38] . These investigators immunized rats with a non-glycosylated fusion protein produced in bacteria that were obtained from a eDNA which they believed encoded for gp330. However, subsequent work has shown that their eDNA actually encoded for RAP [15, [22] [23] [24] . They reported that these rats developed small subcpithelial immune deposits containing endogenous rat IgG in gb-merular capillary wall when sacrificed at 12 weeks. It was not stated as to how many rats were immunized and how many developed immune deposits, and whether the immunized rats developed autoantibodies to the fusion protein in their sera or had abnormal proteinuria. It was also not stated whether the small deposits of rat IgG noted in immunized rat(s) were quantitatively or in their site of location different from the endogenous rat IgO normally detectable in the gbomerulus [39, 40] and whether the deposits stained positively for complement. Also, no studies such as elution of IgG from glomeruli of immunized rats, or other studies to determine if the small amount of the IgG detected in glomeruli was indeed autoantibody to RAP, were performed. In the absence of the above information, it is difficult to know whether the disease of active HN was induced in their study. Our results of induction of a mild passive HN with polyclonal antibody to RAP agree with the results of Pietromonaco et al [38] . However, Pietromanaco et al did not report if rat complement was detectable in the passive HN lesion. We were able to detect complement along with the injected antibody in passive HN; however, no abnormal proteinuria was observed. How do these positive results in passive HN reconcile with the negative results in active HN? We believe this is probably explained by the variation in epitope specificities of the autoantibodies induced by active immunization of rat and those of the polyclonal antibodies induced in rabbit as proposed in another model [41] . Since RAP is a self antigen it is likely that the autoantibodies elicited by rat are to a limited number of epitopes. On the other hand, the polyclonal antibodies are likely to be to many more epitopes. It is possible that polyclonal antibody can find a few reactive epitopes on the small amount of RAP present om glomerular epithelial cells while those epitopes do not react with autoantibodies. Further studies will be needed to resolve this issue. This also raises another general question as to whether the antibodies involved in the active HN induced by immunization with rat FX1A and those involved in the passive model induced by intravenous injection of antiserum to FX1A are to the same antigens and the same epitopes on those antigens.
